Page last updated: 2024-08-17

tetrabenazine and Tardive Dyskinesia

tetrabenazine has been researched along with Tardive Dyskinesia in 86 studies

Research

Studies (86)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	56 (65.12)	24.3611
2020's	30 (34.88)	2.80

Authors

Authors	Studies
Barkay, H; Chaijale, N; Finkbeiner, S; Gordon, MF; Gross, N; Sajatovic, M; Wilhelm, A	1
Barkay, H; Gordon, MF; Hauser, RA; Savola, JM; Wieman, M; Wilhelm, A	1
Nomoto, M	1
Ito, H; Sakata, M	1
Horiguchi, J; Iwatake, A; Kondo, K; Masui, H; Sakamoto, H; Susuta, Y; Watanabe, K; Watanabe, Y	1
Belete, TM	1
Albayrak, Y; Beyazyüz, E; Çelikkol, A; Mengi, M; Uslu, ET	1
Jankovic, J; Makhoul, K	1
Zalyalova, ZA	1
Arya, D; Fernandez, HH; Khan, T; Margolius, AJ	1
Carroll, B; Claassen, DO; Philbin, M	1
Alexopoulos, GS; Burke, J; Farahmand, K; Sajatovic, M; Siegert, S	1
Akbar, U; Friedman, JH; Kim, DS	1
McEvoy, JP	3
Khorassani, F; Luther, K; Talreja, O	1
Shah, C	1
Kremens, DE; McEvoy, JP	1
Citrome, LL	1
Citrome, L; Saklad, SR	1
Grigoriadis, DE; He, W; Huang, M; Kudwa, A; Meltzer, HY; Rajagopal, L	1
Baillie, TA; Bradbury, M; Cox, DS; Hellriegel, E; Loupe, PS; Rabinovich-Guilatt, L; Savola, JM; Schneider, F; Stamler, D	1
Bashir, HH; Jankovic, J	1
Akbostanci, MC; Sahin, T; Yilmaz, R	1
Burke, J; Jimenez, R; Liang, GS; Lindenmayer, JP; Marder, SR; O'Brien, CF; Siegert, S; Verghese, C	1
Dashtipour, K; Koch, J; Shi, WX	1
Piechowski, K; Sizemore, J; Wietholter, JP	2
Bhidayasiri, R; Caroff, SN; Correll, CU; Fahn, S; Frei, KP; Hauser, RA; Jankovic, J; Kane, JM; Truong, DD	1
Dorfman, BJ; Jimenez-Shahed, J	1
Espay, AJ; Gupta, HV; Sharma, VD	1
Alexander, J; Gordon, MF; Knebel, H; Loupe, P; Schneider, F; Wilhelm, A	1
Burke, J; Factor, SA; Hauser, RA; Jimenez, R; Knesevich, MA; Liang, GS; Marder, SR; O'Brien, CF; Ramirez, PM	1
Paton, DM	1
Anderson, KE; Bega, D; Davis, C; Davis, MD; Factor, SA; Fernandez, HH; Hauser, RA; Jarskog, LF; Jimenez-Shahed, J; LeDoux, MS; Meltzer, HY; Ondo, WG; Shprecher, DR; Stamler, D; Woods, SW	1
Birkner, T; Davis, MC; Kalsi, JK; Mathis, MV; Miller, BJ	1
Citrome, L	4
Kim, ES	1
Carbon, M; Correll, CU	1
Anderson, KE; Davis, MD; Factor, SA; Fernandez, HH; Hauser, RA; Isojärvi, J; Jarskog, LF; Jimenez-Shahed, J; Kumar, R; McEvoy, JP; Ochudlo, S; Ondo, WG; Stamler, D	1
Hauser, RA; Seeberger, LC	1
Bozigian, H; Grigoriadis, DE; Loewen, G; O'Brien, CF; Skor, H; Smith, EB	1
Bozigian, H; Jimenez, R; Loewen, G; Luo, R; O'Brien, CF	1
Burke, J; Correll, CU; Josiassen, RC; Liang, GS; O'Brien, CF	1
Burke, J; Josiassen, RC; Kane, JM; Liang, GS; O'Brien, CF	1
Burke, J; Correll, CU; Kane, JM; Liang, GS; O'Brien, CF	1
Harvey, PD; Rosenfeld, A; Strassnig, M	1
Aggarwal, S; Caroff, SN; Yonan, C	1
Müller, T	1
Dietterich, TE; Filmyer, DM; Gillean, J; Josiassen, RC; Shah, SS; Shaughnessy, RA	1
DeWitt, SH; Maryanoff, BE	1
Burke, J; Jimenez, R; Liang, GS; O'Brien, CF; Thai-Cuarto, D	1
Stahl, SM	2
Henchcliffe, C; Sarva, H	1
Cummings, MA; Proctor, GJ; Stahl, SM	1
Morrow, T	1
Nicewonder, JA; Peckham, AM	1
Jankovic, J; Niemann, N	1
Finn, LA; Hussar, DA	1
Baker, DE; Kim, AP; Levien, TL	1
Correll, CU; Kane, JM; Pigato, G; Solmi, M	1
Agboola, F; Atlas, SJ; Curfman, G	1
Bednarczyk, EM; Russak, EM	1
Estevez-Fraga, C; López-Sendón Moreno, JL; Zeun, P	1
Skaff, R	1
Burke, J; Calabrese, JR; Farahmand, K; McIntyre, RS; Nierenberg, AA; Siegert, S; Yonan, C	1
Fernandez, HH; Margolius, A	1
Correll, CU; Cutler, AJ; Kane, JM; Liang, GS; McEvoy, JP; O'Brien, CF	1
Jimenez-Shahed, J; Niemann, N	1
Comella, C; Witek, N	1
Addington, D; Barnes, TRE; Carson, A; Edwards, M; Gardner, D; Martino, D; Morgante, F; Poole, N; Pringsheim, T; Remington, G; Ricciardi, L	1
Limandri, BJ	1
Correll, CU; Cutler, AJ; Kane, JM; Liang, GS; O'Brien, CF; Sajatovic, M; Stacy, M	1
Anderson, KE; Bega, D; Davis, MD; Factor, SA; Fernandez, HH; Hauser, RA; Jarskog, LF; Jimenez-Shahed, J; LeDoux, MS; Ondo, WG; Shprecher, DR; Stamler, D; Woods, SW	1
Friedman, JH	1
Jankovic, J; Vijayakumar, D	1
Jankovic, J	1
Meyer, JM	1
Barquero, N	1

Reviews

34 review(s) available for tetrabenazine and Tardive Dyskinesia

Article	Year
Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer. Drug design, development and therapy, 2022, Volume: 16 Topics: Carbon; Deuterium; Humans; Huntington Disease; Neoplasms; Tardive Dyskinesia; Tetrabenazine	2022
Tardive Dyskinesia: Treatment Update. Current neurology and neuroscience reports, 2019, 08-16, Volume: 19, Issue:9 Topics: Antipsychotic Agents; Dopamine Antagonists; Drug-Related Side Effects and Adverse Reactions; Humans; Quality of Life; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2019
Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:18 Topics: Chorea; Dopamine Antagonists; Humans; Huntington Disease; Quality of Life; Tardive Dyskinesia; Tetrabenazine	2019
FDA-Approved Medications to Treat Tardive Dyskinesia. The Journal of clinical psychiatry, 2019, 12-17, Volume: 81, Issue:1 Topics: Humans; Medication Adherence; Practice Guidelines as Topic; Tardive Dyskinesia; Tetrabenazine; Valine	2019
Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020, Jan-24, Volume: 77, Issue:3 Topics: Humans; Randomized Controlled Trials as Topic; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine; Vesicular Monoamine Transport Proteins	2020
Treatment of Tardive Dyskinesia. Neurologic clinics, 2020, Volume: 38, Issue:2 Topics: Antipsychotic Agents; Botulinum Toxins; Deep Brain Stimulation; Electroconvulsive Therapy; Humans; Muscarinic Antagonists; Neuromuscular Agents; Tardive Dyskinesia; Tetrabenazine; Trihexyphenidyl; Valine; Vesicular Monoamine Transport Proteins	2020
VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Pharmacology & therapeutics, 2020, Volume: 212 Topics: Animals; Chorea; Clinical Trials as Topic; Dopamine; Humans; Huntington Disease; Hyperkinesis; Synaptic Transmission; Tardive Dyskinesia; Tetrabenazine; Vesicular Monoamine Transport Proteins	2020
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism & related disorders, 2020, Volume: 77 Topics: Antipsychotic Agents; Dyskinesias; Humans; Movement Disorders; Outcome Assessment, Health Care; Tardive Dyskinesia; Tetrabenazine	2020
Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome. Drugs of today (Barcelona, Spain : 1998), 2017, Volume: 53, Issue:2 Topics: Adrenergic Uptake Inhibitors; Animals; Drug Approval; Heart Rate; Humans; Huntington Disease; Hyperkinesis; Molecular Structure; Motor Activity; Structure-Activity Relationship; Tardive Dyskinesia; Tetrabenazine; Tourette Syndrome; Treatment Outcome; United States; United States Food and Drug Administration	2017
Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International journal of clinical practice, 2017, Volume: 71, Issue:7 Topics: Central Nervous System Agents; Humans; Numbers Needed To Treat; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine	2017
Valbenazine: First Global Approval. Drugs, 2017, Volume: 77, Issue:10 Topics: Adult; Clinical Trials as Topic; Drug Approval; Humans; Tardive Dyskinesia; Tetrabenazine; Tourette Syndrome; United States; United States Food and Drug Administration; Valine; Vesicular Monoamine Transport Proteins	2017
Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS spectrums, 2018, Volume: 23, Issue:6 Topics: Activities of Daily Living; Cognition; Gait; Humans; Motor Skills; Tardive Dyskinesia; Tetrabenazine	2018
Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. Journal of comparative effectiveness research, 2018, Volume: 7, Issue:2 Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Clinical Trials as Topic; Drug Administration Schedule; Humans; Research Design; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2018
Valbenazine for the treatment of tardive dyskinesia. Expert review of neurotherapeutics, 2017, Volume: 17, Issue:12 Topics: Adrenergic Uptake Inhibitors; Humans; Tardive Dyskinesia; Tetrabenazine; Valine	2017
Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International journal of clinical practice, 2017, Volume: 71, Issue:11 Topics: Adrenergic Uptake Inhibitors; Humans; Nasopharyngitis; Numbers Needed To Treat; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Vesicular Monoamine Transport Proteins	2017
Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects. CNS spectrums, 2018, Volume: 23, Issue:1 Topics: Animals; Corpus Striatum; Dopamine; Humans; Tardive Dyskinesia; Tetrabenazine; Vesicular Monoamine Transport Proteins	2018
Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:3 Topics: Adult; Animals; Antipsychotic Agents; Dopamine; Drug Approval; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2018
Deuterium Tetrabenazine for Tardive Dyskinesia. Clinical schizophrenia & related psychoses, 2018, Volume: 11, Issue:4 Topics: Adrenergic Uptake Inhibitors; Humans; Tardive Dyskinesia; Tetrabenazine; Vesicular Monoamine Transport Proteins	2018
VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications. Journal of pharmacy practice, 2019, Volume: 32, Issue:4 Topics: Adrenergic Uptake Inhibitors; Dopamine Antagonists; Drug Labeling; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2019
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs, 2018, Volume: 78, Issue:5 Topics: Antipsychotic Agents; Drug Approval; Humans; Huntington Disease; Tardive Dyskinesia; Tetrabenazine; Tourette Syndrome; United States; United States Food and Drug Administration; Valine; Vesicular Monoamine Transport Proteins	2018
Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert review of neurotherapeutics, 2018, Volume: 18, Issue:4 Topics: Adrenergic Uptake Inhibitors; Dopamine Antagonists; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2018
VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2018, Apr-01, Volume: 33, Issue:4 Topics: Drug Approval; Humans; Practice Guidelines as Topic; Tardive Dyskinesia; Tetrabenazine; United States; United States Food and Drug Administration; Valine; Vesicular Monoamine Transport Proteins	2018
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug design, development and therapy, 2018, Volume: 12 Topics: Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2018
Effectiveness and Value of 2 Novel Treatments for Tardive Dyskinesia. JAMA internal medicine, 2018, 08-01, Volume: 178, Issue:8 Topics: Humans; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine	2018
Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. The Annals of pharmacotherapy, 2019, Volume: 53, Issue:2 Topics: Chorea; Deuterium; Drug Approval; Humans; Huntington Disease; Legislation, Drug; Pharmaceutical Preparations; Pharmacokinetics; Tardive Dyskinesia; Tetrabenazine; Toxicity Tests; United States; United States Food and Drug Administration	2019
Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS spectrums, 2018, Volume: 23, Issue:4 Topics: Adrenergic Uptake Inhibitors; Animals; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2018
Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly. Drugs & aging, 2018, Volume: 35, Issue:11 Topics: Aged; Dementia; Dyskinesia, Drug-Induced; Humans; Parkinsonian Disorders; Risk Factors; Tardive Dyskinesia; Tetrabenazine; Valine	2018
Current treatment of tardive dyskinesia. Parkinsonism & related disorders, 2019, Volume: 59 Topics: Antioxidants; Antipsychotic Agents; Dopamine Antagonists; GABA Modulators; Humans; Tardive Dyskinesia; Tetrabenazine; Vesicular Monoamine Transport Proteins	2019
Treatment Recommendations for Tardive Dyskinesia. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2019, Volume: 64, Issue:6 Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Humans; Tardive Dyskinesia; Tetrabenazine; Valine	2019
Tardive Syndromes. Continuum (Minneapolis, Minn.), 2019, Volume: 25, Issue:4 Topics: Aged; Antioxidants; Antipsychotic Agents; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Tardive Dyskinesia; Tetrabenazine; Vesicular Monoamine Transport Proteins	2019
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs, 2016, Volume: 76, Issue:7 Topics: Antipsychotic Agents; Botulinum Toxins; Dopamine Antagonists; Dyskinesia, Drug-Induced; Humans; Male; Middle Aged; Parkinson Disease; Quality of Life; Tardive Dyskinesia; Tetrabenazine	2016
Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:18 Topics: Animals; Antipsychotic Agents; Dopamine; Dopamine Antagonists; Humans; Huntington Disease; Hyperkinesis; Movement Disorders; Receptors, Dopamine; Tardive Dyskinesia; Tetrabenazine; Tics; Treatment Outcome	2016
Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS spectrums, 2016, Volume: 21, Issue:S1 Topics: Adrenergic Uptake Inhibitors; Amantadine; Antipsychotic Agents; Clonazepam; Dopamine Agents; Dopamine Antagonists; GABA Modulators; Ginkgo biloba; Humans; Plant Extracts; Risk Factors; Tardive Dyskinesia; Tetrabenazine; Valine	2016
Valbenazine for the treatment of tardive dyskinesia. Drugs of today (Barcelona, Spain : 1998), 2016, Volume: 52, Issue:12 Topics: Animals; Dopamine; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2016

Trials

15 trial(s) available for tetrabenazine and Tardive Dyskinesia

Article	Year
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine. Parkinsonism & related disorders, 2022, Volume: 97 Topics: Abnormal Involuntary Movement Scale; Antipsychotic Agents; Humans; Tardive Dyskinesia; Tetrabenazine	2022
Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT). Psychiatry and clinical neurosciences, 2022, Volume: 76, Issue:11 Topics: Adult; Antipsychotic Agents; Double-Blind Method; Humans; Japan; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome	2022
The effects of valbenazine on tardive dyskinesia in older and younger patients. International journal of geriatric psychiatry, 2020, Volume: 35, Issue:1 Topics: Adult; Age Factors; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine	2020
Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV-50717) Compared With Tetrabenazine in Healthy Volunteers. Clinical and translational science, 2020, Volume: 13, Issue:4 Topics: Administration, Oral; Adolescent; Adrenergic Uptake Inhibitors; Adult; Area Under Curve; Cross-Over Studies; Female; Healthy Volunteers; Humans; Huntington Disease; Male; Tardive Dyskinesia; Tetrabenazine; Young Adult	2020
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. The American journal of psychiatry, 2017, 05-01, Volume: 174, Issue:5 Topics: Abnormal Involuntary Movement Scale; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mood Disorders; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine	2017
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology, 2017, May-23, Volume: 88, Issue:21 Topics: Comorbidity; Double-Blind Method; Europe; Female; Humans; Least-Squares Analysis; Male; Mental Disorders; Middle Aged; Neuromuscular Agents; Severity of Illness Index; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; United States	2017
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. The lancet. Psychiatry, 2017, Volume: 4, Issue:8 Topics: Abnormal Involuntary Movement Scale; Adult; Aged; Double-Blind Method; Dyskinesias; Europe; Female; Humans; Male; Middle Aged; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; United States	2017
Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects. Psychopharmacology bulletin, 2017, 08-01, Volume: 47, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Healthy Volunteers; Humans; Male; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacology bulletin, 2017, 08-01, Volume: 47, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mood Disorders; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2017
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Psychopharmacology bulletin, 2017, 08-01, Volume: 47, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Long Term Adverse Effects; Male; Middle Aged; Mood Disorders; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacology bulletin, 2017, 08-01, Volume: 47, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2017
The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. Journal of affective disorders, 2019, 03-01, Volume: 246 Topics: Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Mood Disorders; Tardive Dyskinesia; Tetrabenazine; Valine	2019
Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study. The Journal of clinical psychiatry, 2018, 12-18, Volume: 80, Issue:1 Topics: Adrenergic Uptake Inhibitors; Affective Disorders, Psychotic; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Least-Squares Analysis; Outcome Assessment, Health Care; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine	2018
Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:8 Topics: Aged; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Minimal Clinically Important Difference; Mood Disorders; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine; Vesicular Monoamine Transport Proteins	2019
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. Journal of neurology, neurosurgery, and psychiatry, 2019, Volume: 90, Issue:12 Topics: Adult; Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Mood Disorders; Psychotic Disorders; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome	2019

Other Studies

37 other study(ies) available for tetrabenazine and Tardive Dyskinesia

Article	Year
Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2022, Volume: 30, Issue:3 Topics: Adrenergic Uptake Inhibitors; Aged; Humans; Middle Aged; Quality of Life; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome	2022
[Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Treatments for Tardive Dyskinesia]. Brain and nerve = Shinkei kenkyu no shinpo, 2022, Volume: 74, Issue:5 Topics: Antipsychotic Agents; Dopamine Antagonists; Humans; Schizophrenia; Tardive Dyskinesia; Tetrabenazine	2022
[Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Management of Tardive Dyskinesia Based on the Latest Knowledge]. Brain and nerve = Shinkei kenkyu no shinpo, 2022, Volume: 74, Issue:5 Topics: Antipsychotic Agents; Dyskinesias; Humans; Schizophrenia; Tardive Dyskinesia; Tetrabenazine	2022
The effects of sigma-1 agonist fluvoxamine on experimental induced tardive dyskinesia model in rats. Progress in neuro-psychopharmacology & biological psychiatry, 2023, Aug-30, Volume: 126 Topics: Animals; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Dyskinesias; Fluvoxamine; Haloperidol; Male; Nerve Growth Factor; Rats; Rats, Wistar; Superoxide Dismutase; Tardive Dyskinesia; Tetrabenazine	2023
Real-world experience with VMAT2 inhibitors in Tourette syndrome. Journal of neurology, 2023, Volume: 270, Issue:9 Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Retrospective Studies; Tardive Dyskinesia; Tetrabenazine; Tics; Tourette Syndrome; United States; Vesicular Monoamine Transport Proteins	2023
[Tardive dyskinesia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2023, Volume: 123, Issue:7 Topics: Amantadine; Antipsychotic Agents; Humans; Tardive Dyskinesia; Tetrabenazine	2023
Valbenazine-induced parkinsonism. Parkinsonism & related disorders, 2020, Volume: 70 Topics: Adrenergic Uptake Inhibitors; Adult; Affective Disorders, Psychotic; Aged; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease, Secondary; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2020
Comment on Akbar et al., "Valbenazine-induced parkinsonism". Parkinsonism & related disorders, 2020, Volume: 71 Topics: Antipsychotic Agents; Humans; Parkinsonian Disorders; Tardive Dyskinesia; Tetrabenazine; Valine	2020
Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia. The Journal of clinical psychiatry, 2020, Jan-28, Volume: 81, Issue:1 Topics: Antipsychotic Agents; Diagnosis, Differential; Drug Monitoring; Early Diagnosis; Humans; Membrane Transport Modulators; Mood Disorders; Patient Care; Patient Education as Topic; Psychology; Risk Assessment; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine	2020
Medication Options and Clinical Strategies for Treating Tardive Dyskinesia. The Journal of clinical psychiatry, 2020, Jan-28, Volume: 81, Issue:2 Topics: Drug Monitoring; Humans; Medication Therapy Management; Membrane Transport Modulators; Neurologic Examination; Patient Care Management; Psychiatry; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine; Vesicular Monoamine Transport Proteins	2020
Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment. The Journal of clinical psychiatry, 2020, 02-18, Volume: 81, Issue:2 Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Diagnosis, Differential; Dopamine Antagonists; Female; Humans; Male; Middle Aged; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2020
Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action. Pharmacology, biochemistry, and behavior, 2020, Volume: 190 Topics: Animals; Antipsychotic Agents; Dopamine; Hippocampus; Locomotion; Male; Mice; Mice, Inbred C57BL; Microdialysis; Nucleus Accumbens; Phencyclidine; Prefrontal Cortex; Serotonin; Synaptic Transmission; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2020
Predictive factors for tolerability of tetrabenazine in patients with hyperkinetic movement disorders. Parkinsonism & related disorders, 2020, Volume: 74 Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Chorea; Drug-Related Side Effects and Adverse Reactions; Dystonic Disorders; Female; Humans; Hyperkinesis; Male; Middle Aged; Movement Disorders; Parkinson Disease, Secondary; Tardive Dyskinesia; Tetrabenazine; Tic Disorders; Turkey; Young Adult	2020
A long-term, open-label study of valbenazine for tardive dyskinesia. CNS spectrums, 2021, Volume: 26, Issue:4 Topics: Adrenergic Uptake Inhibitors; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Satisfaction; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine	2021
Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020, 09-04, Volume: 77, Issue:18 Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Female; Gastrostomy; Humans; Severity of Illness Index; Tablets; Tardive Dyskinesia; Tetrabenazine	2020
Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence. The Journal of clinical psychiatry, 2020, 09-29, Volume: 81, Issue:6 Topics: Adrenergic Uptake Inhibitors; Adult; Clozapine; Humans; Psychiatry; Serotonin Antagonists; Tardive Dyskinesia; Tetrabenazine; Valine	2020
How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care. The Journal of clinical psychiatry, 2020, 11-03, Volume: 81, Issue:6 Topics: Adrenergic Uptake Inhibitors; Adult; Humans; Outcome Assessment, Health Care; Psychiatry; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2020
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia. Expert review of neurotherapeutics, 2021, Volume: 21, Issue:1 Topics: Dyskinesias; Humans; Tardive Dyskinesia; Tetrabenazine; United States; Vesicular Monoamine Transport Proteins	2021
Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia. Tremor and other hyperkinetic movements (New York, N.Y.), 2020, 12-16, Volume: 10 Topics: Adrenergic beta-Antagonists; Aged; Aripiprazole; Clonazepam; Deprescriptions; Depressive Disorder; Drug Substitution; GABA Modulators; Humans; Male; Parkinsonian Disorders; Pelvis; Propranolol; Quinolones; Serotonin Agents; Tardive Dyskinesia; Tetrabenazine; Thiophenes; Treatment Failure; Valine	2020
Crushing of deutetrabenazine tablets limited to individual case. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2021, 08-30, Volume: 78, Issue:17 Topics: Humans; Tablets; Tardive Dyskinesia; Tetrabenazine	2021
On crushing of deutetrabenazine tablets. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2021, 08-30, Volume: 78, Issue:17 Topics: Humans; Tablets; Tardive Dyskinesia; Tetrabenazine	2021
Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia. The New England journal of medicine, 2017, Jun-29, Volume: 376, Issue:26 Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Dopamine; Drug Approval; Humans; Synaptic Transmission; Tardive Dyskinesia; Tetrabenazine; United States; United States Food and Drug Administration; Valine; Vesicular Monoamine Transport Proteins	2017
Valbenazine (Ingrezza) for tardive dyskinesia. The Medical letter on drugs and therapeutics, 2017, 05-22, Volume: 59, Issue:1521 Topics: Antipsychotic Agents; Humans; Neurotransmitter Uptake Inhibitors; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine; Vesicular Monoamine Transport Proteins	2017
A new class of VMAT-2 inhibitors for tardive dyskinesia. The lancet. Psychiatry, 2017, Volume: 4, Issue:8 Topics: Antipsychotic Agents; Double-Blind Method; Dyskinesias; Humans; Tardive Dyskinesia; Tetrabenazine	2017
Valbenazine for the treatment of tardive dyskinesia. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:12 Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Mental Disorders; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine; Vesicular Monoamine Transport Proteins	2017
Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine. Drugs in R&D, 2017, Volume: 17, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Chromatography, Liquid; Female; Humans; Huntington Disease; Isomerism; Male; Middle Aged; Tandem Mass Spectrometry; Tardive Dyskinesia; Tetrabenazine; Valine	2017
Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective. The American journal of case reports, 2017, Nov-08, Volume: 18 Topics: Adrenergic Uptake Inhibitors; Antimanic Agents; Female; Humans; Middle Aged; Tardive Dyskinesia; Tetrabenazine; Valine	2017
Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine Biochemistry, 2018, 02-06, Volume: 57, Issue:5 Topics: Adrenergic Uptake Inhibitors; Animals; Biochemistry; Chorea; Deuterium; Drug and Narcotic Control; Drug Approval; Drug Discovery; Humans; Tardive Dyskinesia; Tetrabenazine	2018
Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials. Drug safety, 2018, Volume: 41, Issue:4 Topics: Aged; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Heart Rate; Humans; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Tardive Dyskinesia; Tetrabenazine; Valine	2018
Two New Drugs for Tardive Dyskinesia Hit the Market. Managed care (Langhorne, Pa.), 2018, Volume: 27, Issue:1 Topics: Antipsychotic Agents; Drug Approval; Humans; Managed Care Programs; Tardive Dyskinesia; Tetrabenazine; United States; United States Food and Drug Administration; Valine	2018
2018 New Drug Update. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2018, Apr-01, Volume: 33, Issue:4 Topics: Aged; Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiparkinson Agents; Benzamides; Benzylamines; Constipation; Drug Approval; Humans; Natriuretic Peptides; Psoriasis; Pyridines; Tardive Dyskinesia; Tetrabenazine; Valine	2018
Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia. The Medical letter on drugs and therapeutics, 2018, 04-23, Volume: 60, Issue:1545 Topics: Adrenergic Uptake Inhibitors; Drug Costs; Drug Interactions; Humans; Huntington Disease; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Vesicular Monoamine Transport Proteins	2018
Vesicular monoamine transporter type 2 inhibition can lead to effective and tolerable management of tardive dyskinesia. Evidence-based mental health, 2018, Volume: 21, Issue:3 Topics: Double-Blind Method; Dyskinesias; Humans; Tardive Dyskinesia; Tetrabenazine; Vesicular Monoamine Transport Proteins	2018
Valbenazine and Deutetrabenazine as possible treatments for neuroleptic-induced supersensitivity psychosis and antipsychotic dependence. CNS spectrums, 2019, Volume: 24, Issue:4 Topics: Antipsychotic Agents; Dopamine; Humans; Psychotic Disorders; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2019
Deutetrabenazine in the treatment of tardive dyskinesia. Neurodegenerative disease management, 2019, Volume: 9, Issue:2 Topics: Adrenergic Uptake Inhibitors; Clinical Trials as Topic; Dopamine Antagonists; Humans; Outcome Assessment, Health Care; Tardive Dyskinesia; Tetrabenazine; Vesicular Monoamine Transport Proteins	2019
Valbenazine in the treatment of tardive dyskinesia. Neurodegenerative disease management, 2019, Volume: 9, Issue:2 Topics: Adrenergic Uptake Inhibitors; Dopamine Antagonists; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2019
Tardive Dyskinesia: New Treatments Available. Journal of psychosocial nursing and mental health services, 2019, May-01, Volume: 57, Issue:5 Topics: Antipsychotic Agents; Chlorpromazine; Drug-Related Side Effects and Adverse Reactions; Humans; Psychiatric Nursing; Tardive Dyskinesia; Tetrabenazine; Valine	2019